Aptevo Therapeutics Inc (APVO)
NASDAQ:APVO
Want to see APVO full AI Analyst Report?
APVO Stock Chart & Stats
$0.61
-$0.30(-5.81%)
At close: 4:00 PM EST
$0.61
-$0.30(-5.81%)
Day’s Range― - ―
52-Week Range$3.80 - $235.96
Previous CloseN/A
Volume25.11K
Average Volume (3M)11.64M
Market Cap
$6.28M
Enterprise Value$721.94K
Total Cash (Recent Filing)$14.53M
Total Debt (Recent Filing)$4.42M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-357.16
Shares Outstanding1,246,105
10 Day Avg. Volume7,942,705
30 Day Avg. Volume11,635,265
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.22
Enterprise Value/Ebitda-0.03
Forecast
1Y Price Target
$21.00Price Target Upside3342.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-20.99
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial Efficacy & SafetyRobust Phase 1b results with high benefit and remission rates plus no cytokine release syndrome signal a durable clinical differentiation for mipletamig. This strengthens development momentum, improves chances of favorable Phase 2 design and partner interest, and supports a credible regulatory path in AML over the next 2–6 months.
Proprietary Platform AdvantageOwning the ADAPTIR/ADAPTIR-FLEX engineering platforms provides a structural competitive edge: it enables multiple candidate generation, supports potential collaboration/licensing revenue streams, and creates barrier-to-entry advantages that can sustain pipeline expansion and partner economics beyond short-term trial outcomes.
Moderate Leverage And Positive EquityImproved leverage and positive equity reduce immediate solvency pressure relative to prior periods, giving management structural flexibility to advance clinical programs and negotiate partnerships. This stronger balance-sheet posture lessens near-term default risk and supports execution of the RAINIER program over several quarters.
Bears Say
High Cash BurnSustained negative operating and free cash flow of roughly $27M TTM is a persistent funding constraint: it forces reliance on external financing or collaborations, compresses runway, and can slow trial timelines if capital access tightens, creating structural execution risk over the medium term.
No Meaningful Revenue And Persistent LossesWith no recurring product revenue and sizable ongoing losses, Aptevo lacks organic cash generation to fund development. This structural dependence on milestone/collaboration payments raises volatility in funding availability and increases the probability of dilutive financings if partnerships or milestones do not materialize.
Dilution / Financing RiskAuthorization to issue more than 19.99% of shares under a standby equity facility materially increases the company's ability to raise equity but also raises the structural risk of dilution. Over coming quarters this can weigh on shareholder returns and complicate incentive alignment when frequent equity financing is anticipated.
Aptevo Therapeutics News
APVO FAQ
What was Aptevo Therapeutics Inc’s price range in the past 12 months?
Aptevo Therapeutics Inc lowest stock price was $3.80 and its highest was $235.96 in the past 12 months.
What is Aptevo Therapeutics Inc’s market cap?
Aptevo Therapeutics Inc’s market cap is $6.28M.
When is Aptevo Therapeutics Inc’s upcoming earnings report date?
Aptevo Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 74 days.
How were Aptevo Therapeutics Inc’s earnings last quarter?
Aptevo Therapeutics Inc released its earnings results on May 07, 2026. The company reported -$6.405 earnings per share for the quarter, beating the consensus estimate of -$6.41 by $0.005.
Is Aptevo Therapeutics Inc overvalued?
According to Wall Street analysts Aptevo Therapeutics Inc’s price is currently Undervalued.
Does Aptevo Therapeutics Inc pay dividends?
Aptevo Therapeutics Inc does not currently pay dividends.
What is Aptevo Therapeutics Inc’s EPS estimate?
Aptevo Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aptevo Therapeutics Inc have?
Aptevo Therapeutics Inc has 1,246,105 shares outstanding.
What happened to Aptevo Therapeutics Inc’s price movement after its last earnings report?
Aptevo Therapeutics Inc reported an EPS of -$6.405 in its last earnings report, beating expectations of -$6.41. Following the earnings report the stock price went down -1.619%.
Which hedge fund is a major shareholder of Aptevo Therapeutics Inc?
Currently, no hedge funds are holding shares in APVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
APVO Stock 12 Month Forecast
Average Price Target
$21.00
▲(3342.62% Upside)
Technical Analysis
Ownership Overview
1.09% Insiders
1.79% Mutual Funds
<0.01% Other Institutional Investors
96.10% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---